NCT00965627

Brief Summary

This is a retrospective analysis of biological characteristics of thymoma and thymic carcinoma patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
134

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2009

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

August 6, 2009

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 25, 2009

Completed
Last Updated

August 28, 2009

Status Verified

August 1, 2009

Enrollment Period

2 months

First QC Date

August 6, 2009

Last Update Submit

August 27, 2009

Conditions

Thymoma

Outcome Measures

Primary Outcomes (1)

  • Primary objective: to evaluate the presence of genetic alterations and specific potential therapy targets.

    one year

Secondary Outcomes (1)

  • Secondary objective: to correlate the biological characteristics with clinical characteristics and survival data of patients.

    one year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Thymoma and thymic carcinoma patients will be retrospectively analyzed. Patients will be selected based on the availability of tumor tissue.

You may qualify if:

  • Availability of tumor tissue and patients with thymoma and thymic carcinoma

You may not qualify if:

  • NON Availability of tumor tissue and patients with thymoma and thymic carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituto Clinico Humanitas

Rozzano, Milano, 20089, Italy

Location

Related Publications (1)

  • Petrini I, Wang Y, Zucali PA, Lee HS, Pham T, Voeller D, Meltzer PS, Giaccone G. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res. 2013 Apr 15;19(8):1960-71. doi: 10.1158/1078-0432.CCR-12-3260. Epub 2013 Feb 26.

    PMID: 23444221DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

paraffin-embedded tumor specimens of patients

MeSH Terms

Conditions

Thymoma

Condition Hierarchy (Ancestors)

Neoplasms, Complex and MixedNeoplasms by Histologic TypeNeoplasmsThymus NeoplasmsThoracic NeoplasmsNeoplasms by SiteLymphatic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Armando Santoro, MD

    Istituto Clinico Humanitas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 6, 2009

First Posted

August 25, 2009

Study Start

June 1, 2008

Primary Completion

August 1, 2008

Study Completion

August 1, 2009

Last Updated

August 28, 2009

Record last verified: 2009-08

Locations

IT(1)